|
JOHNS HOPKINS
UNIVERSITY (JHU)
|
|
JHU 4429
|
Adenovirus Vaccine Vectors: Viable Recombinant
Adenoviruses that Direct High-Level Antigen Expression
|
|
JHU 4347
|
Use of Oxylipins and Bacterial Phytotoxins as Immunosuppressive
and Anti-Viral Agents*
|
|
|
|
|
JHU 4089
|
Polyamine Analogues with Significant Antitumor and
Antiparasitic Activity*
|
|
JHU 4054
|
Johns Hopkins
Point of Care Information Technology (POC-IT)
|
|
JHU 1703
|
O2-Benzyl-Substituted Dizeniumdiolates that Release
Nitric Oxide at Controlled Rates Upon Photolysis
|
|
|
|
|
UNIVERSITY OF MARYLAND, BALTIMORE
|
|
|
|
|
FN-98-001
|
gua Mutants of Salmonella typhi as Mucosal
Live Typhoid Vaccines & Delivery Systems for Recombinant
Antigens and Nucleic Acid Vaccines**
|
|
|
|
|
UNIVERSITY OF
MARYLAND, COLLEGE PARK
|
|
|
|
|
|
Database
Search
|
|
|
|
|
NATIONAL INSTITUTES
OF HEALTH (NIH)
|
|
E-303-2003
|
Vaccines
Using Universally Inactivated Viruses, Parasites, and Tumor Cells
|
|
E-241-2001
|
Improved
Non-Viral Mammalian Expression Vector
|
|
E-247-2002
|
Modulators
of Nuclear Hormone Receptor Activity: Novel Compounds, Diverse
Applications for Infectious Diseases, Including Anthrax (B.
anthracis)
|
|
E-296-2001
|
Alleviating
Symptoms of Th2-Like Cytokine Mediated Disorders by Reducing IL-13
Receptor-Expressing Cells in the Respiratory Tract*
|
|
E-257-2000
|
Bacteriophage
Having Multiple Host Range
|
|
E-126-2000
|
A
Method for Bioconjugation Using Diels-Alder Cycloaddition
|
|
E-199-1999
|
Mycolactone
and Related Compounds
|
|
E-020-1999
|
A
Method of Immunizing Humans Against Salmonella typhi Using a
Vi-rEPA Conjugate Vaccine
|
|
E-290-1997
|
G-Protein
Coupled Receptor Antagonists
|
|
E-095-1997
|
Linking
Compounds Useful for Coupling Carbohydrates to Amine-Containing
Carriers
|
|
E-202-1994
|
Synthesis
of Typhoid Fever Vaccine from a Plant or Fruit Polysaccharide
|
|
E-089-2002
|
Dengue
Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in
the 3'-UTR of Dengue Types 1, 2, 3, and 4
|
|
|
|
|
* Some
technologies have multiple potential uses.
|
|
** These
technologies are related to putting specific vaccines into
bacterial delivery systems, so they are adaptable for any disease.
|
